News

The first-in-class mutant collagenase RJV001 successfully passed the phase I clinical trial in the United States

On June 13, 2022, the US FDA approved the phase I clinical trial of the RJV001 (NCT04821648). A total of 18 patients were enrolled and reached the end of the study, and all three doses were safe and well-tolerated. The ultrasound results showed reduced fat tissue thickness for the exploratory purpose of efficacy. The phase I clinical trial results indicated that RJV001 with mild side effects and early signs of efficacy. The phase II clinical trial protocol is currently in preparation.


dd52bf352c3ef077530866bd1459778.png

Copyright © 2019 Hangzhou Rejuven Dermaceutical Co., Ltd. All Rights Reserved Zhejiang Public Network Security No. 330108020005711备案号:浙ICP备15013641号